Tagrisso clinical trials
Tagrisso is named as an intervention in 28 current clinical trials in our China, South Korea, USA, Spain, Taiwan, Israel, Italy, UK, Germany, Japan, France, Poland, Turkey, Canada, Brazil, Singapore, Belgium, Switzerland, Australia, India, Mexico, Austria, Netherlands, Sweden, Denmark and Norway registers. 12 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (9). The most-studied condition is Non-Small Cell Lung Cancer.
Patient leaflets for Tagrisso
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Tagrisso
28 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tagrisso
28 conditionsAll 28 conditions
| Condition (as registered) | Trials |
|---|---|
| Non-Small Cell Lung Cancer | 5 |
| NSCLC | 3 |
| Lung Cancer | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| EGFR Activating Mutation | 2 |
| Stage II-IIIB Non-small Cell Lung Carcinoma | 1 |
| Cancer | 1 |
| Carcinoma | 1 |
| Non-Small-Cell Lung | 1 |
| Metastatic Non-small Cell Lung Cancer | 1 |
| Carcinoma, Non-Small Cell Lung | 1 |
| Solid Tumor, Adult | 1 |
| Carcinoma, Squamous Cell | 1 |
| Brain Metastases | 1 |
| Non-Small Cell Lung Cancer With EGFR Mutation | 1 |
| Non Small Cell Lung Cancer (NSCLC) | 1 |
| NSCLC, Stage I | 1 |
| NSCLC Stage IIIB | 1 |
| NSCLC Stage IV | 1 |
| EGFR Positive Non-small Cell Lung Cancer | 1 |
| Oligoprogression | 1 |
| Non Small Cell Lung Cancer | 1 |
| Recurrent Lung Non-Small Cell Carcinoma | 1 |
| Stage IV Lung Cancer AJCC v8 | 1 |
| Lung Adenocarcinoma | 1 |
| Locally Advanced or Metastatic NSCLC | 1 |
| Non-squamous NSCLC | 1 |
| Non-small Cell Lung Cancer | 1 |
Sponsors
lead sponsor per trial+ 2 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tagrisso trials
How many clinical trials are testing Tagrisso?
28 current trials in our China, South Korea, USA, Spain, Taiwan, Israel, Italy, UK, Germany, Japan, France, Poland, Turkey, Canada, Brazil, Singapore, Belgium, Switzerland, Australia, India, Mexico, Austria, Netherlands, Sweden, Denmark and Norway registers name Tagrisso as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Tagrisso trials recruiting patients?
Yes. 12 of the 28 trials are recruiting: 7 with sites in China, 1 with sites in South Korea, 1 with sites in USA, 1 with sites in Israel, 1 with sites in Germany and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tagrisso clinical trials?
AstraZeneca (9), Dana-Farber Cancer Institute (3), TYK Medicines, Inc (2) and Genprex, Inc (1), among 17 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tagrisso works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tagrisso works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tagrisso (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.